** California-based drugmaker Gilead Sciences GILD.O posted Q4 results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday driven by 16% jump in HIV drug sales and lower acquisition-related costs
** Shares of GILD up 4.54% at $100.50 in premarket trading on Wednesday
A HEALTHY PROGNOSIS
** J.P.Morgan ("overweight," PT: $120) sees developments in HIV prevention and treatment, oncology, and a new drug launch for primary biliary cholangitis $(PBC)$ in 2025, leading to optimism about co's future
** Mizuho ("outperform," PT: $100) sees strong HIV sales growth but anticipates a significant headwind in 2025 due to Medicare changes
** Piper Sandler ("overweight," PT: $110) sees strong growth in HIV and liver disease treatments, stable FY25 revenue despite headwinds, and anticipates operating margin expansion and key clinical milestones
** RBC Capital Markets ("sector perform," PT: $90) says they are cautious about complexities and costs associated with CAR-T for cancer treatment and ongoing launch of lena PrEP- a preventative HIV drug
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。